The Impact of COVID-19 on People Living with HIV-1 and HIV-1-Associated Neurological Complications
暂无分享,去创建一个
[1] M. Augello,et al. Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames? , 2023, Current HIV/AIDS Reports.
[2] G. Prince,et al. SARS-CoV-2 infection augments species- and age-specific predispositions in cotton rats , 2023, Scientific Reports.
[3] E. Topol,et al. Long COVID: major findings, mechanisms and recommendations , 2023, Nature Reviews Microbiology.
[4] A. Padovani,et al. Looking for lights in the fog of long-term neurological COVID , 2022, Nature Reviews Neurology.
[5] S. Arora,et al. Clinical outcome of patients with HIV/SARS-COV-2 co-infection , 2022, Medical Journal Armed Forces India.
[6] T. Woodruff,et al. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein , 2022, Molecular Psychiatry.
[7] O. Polo,et al. Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome , 2022, Frontiers in Immunology.
[8] F. Dentali,et al. Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications , 2022, eBioMedicine.
[9] C. Demoliou,et al. SARS-CoV-2 and HIV-1: So Different yet so Alike. Immune Response at the Cellular and Molecular Level , 2022, International journal of medical sciences.
[10] Z. Al-Aly,et al. Long-term neurologic outcomes of COVID-19 , 2022, Nature Medicine.
[11] S. Shoptaw,et al. Methamphetamine use and adoption of preventive behaviors early in the COVID-19 pandemic among men who have sex with men in Los Angeles, California , 2022, Drug and Alcohol Dependence Reports.
[12] R. Radhakrishnan,et al. Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study. , 2022, The Journal of clinical psychiatry.
[13] Doron Betel,et al. SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells , 2022, Nature communications.
[14] Gaurav,et al. Putative role of mitochondria in SARS-CoV-2 mediated brain dysfunctions: a prospect. , 2022, Biotechnology & genetic engineering reviews.
[15] M. Gandhi,et al. COVID-19 Outcomes and Risk Factors Among People Living with HIV , 2022, Current HIV/AIDS Reports.
[16] F. Ceccherini‐Silberstein,et al. Neuro-Axonal Damage and Alteration of Blood–Brain Barrier Integrity in COVID-19 Patients , 2022, Cells.
[17] S Spudich,et al. Neuropathogenesis of HIV-1: insights from across the spectrum of acute through long-term treated infection , 2022, Seminars in Immunopathology.
[18] W. Robinson,et al. SARS-CoV-2 infection of monocytes: balancing acts of antibodies and inflammasomes , 2022, Signal Transduction and Targeted Therapy.
[19] M. Peluso,et al. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection , 2022 .
[20] T. Swartz,et al. Inflammasomes as mediators of inflammation in HIV-1 infection. , 2022, Translational research : the journal of laboratory and clinical medicine.
[21] Nishant Singh,et al. COVID-19 Diagnosis: A Comprehensive Review of the RT-qPCR Method for Detection of SARS-CoV-2 , 2022, Diagnostics.
[22] A. Rodrigues,et al. SARS-CoV-2 seroprevalence among people living with HIV in Guinea–Bissau , 2022, Public Health.
[23] Weiming Tang,et al. Systematic Review and Meta-Analyses of The Interaction Between HIV Infection And COVID-19: Two Years’ Evidence Summary , 2022, Frontiers in Immunology.
[24] Randolph D. Hubach,et al. From crisis to crisis: impacts of the COVID-19 pandemic on people living with HIV and HIV/AIDS service organizations in Indiana , 2022, BMC Health Services Research.
[25] K. Liang,et al. COVID-19 Vaccination Willingness Among People Living With HIV in Wuhan, China , 2022, Frontiers in Public Health.
[26] Y. Yazdanpanah,et al. Risk Factors Associated with Severe/Critical COVID-19 in People Living with HIV-1 , 2022, International Journal of Infectious Diseases.
[27] Ye-ming Wang,et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study , 2022, The Lancet Respiratory Medicine.
[28] M. Boks,et al. Characterization of HIV-1 Infection in Microglia-Containing Human Cerebral Organoids , 2022, Viruses.
[29] Samuele Gardin,et al. Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA , 2022, Viruses.
[30] Sonia Tarazona,et al. Association Between Sex Hormone Levels and Clinical Outcomes in Patients With COVID-19 Admitted to Hospital: An Observational, Retrospective, Cohort Study , 2022, Frontiers in Immunology.
[31] J. Freer,et al. HIV and covid-19 in South Africa , 2022, BMJ.
[32] M. Safford,et al. Health Status, Persistent Symptoms, and Effort Intolerance One Year After Acute COVID-19 Infection , 2022, Journal of General Internal Medicine.
[33] A. Nath,et al. Nervous system consequences of COVID-19 , 2022, Science.
[34] Jinpyo Hong,et al. SARS-CoV-2 spike protein induces cognitive deficit and anxiety-like behavior in mouse via non-cell autonomous hippocampal neuronal death , 2022, Scientific Reports.
[35] Karan Varshney,et al. Risk Factors for COVID-19 Mortality Among People Living with HIV: A Scoping Review , 2022, AIDS and Behavior.
[36] Inyoul Y. Lee,et al. Multiple early factors anticipate post-acute COVID-19 sequelae , 2022, Cell.
[37] M. T. McIntosh,et al. SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway , 2022, Virology.
[38] T. Burki. The origin of SARS-CoV-2 variants of concern , 2022, The Lancet. Infectious diseases.
[39] Joohyun Park,et al. Risk factors for COVID-19 among persons with substance use disorder (PWSUD) with hospital visits – United States, April 2020–December 2020 , 2022, Drug and Alcohol Dependence.
[40] S. Maier,et al. SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties , 2021, Brain, Behavior, and Immunity.
[41] F. Kobeissy,et al. SARS-CoV-2 involvement in central nervous system tissue damage , 2021, Neural regeneration research.
[42] S. Kent,et al. Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection , 2021, medRxiv.
[43] Tony Y. Hu,et al. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates , 2020, Nature Communications.
[44] A. Salonia,et al. Low testosterone levels predict clinical adverse outcomes in SARS‐CoV‐2 pneumonia patients , 2020, The Journal of Sexual Medicine.
[45] H. Xiong,et al. NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes. , 2022, International journal of physiology, pathophysiology and pharmacology.
[46] Keshab Subedi,et al. Characteristics and Outcomes of SARS-CoV-2 Infection Among Adults Living With HIV In Delaware: , 2021, Delaware journal of public health.
[47] A. Tall,et al. Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein , 2021, Scientific Reports.
[48] J. Lv,et al. Role of asymptomatic and pre-symptomatic infections in covid-19 pandemic , 2021, BMJ.
[49] E. Akıncı,et al. Neurological Presentations in Patients with COVID-19 in Cytokine Storm , 2021, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[50] O. Olajide,et al. SARS-CoV-2 Spike Glycoprotein S1 Induces Neuroinflammation in BV-2 Microglia , 2021, Molecular Neurobiology.
[51] G. Pentón-Rol,et al. The microglial NLRP3 inflammasome is involved in human SARS-CoV-2 cerebral pathogenicity: A report of three post-mortem cases , 2021, Journal of Neuroimmunology.
[52] A. Adimora,et al. SARS-CoV-2 Infection Among People Living With HIV Compared to People Without HIV , 2021, JAIDS Journal of Acquired Immune Deficiency Syndromes.
[53] Maaged A Akiel,et al. SARS-CoV-2 Coronavirus Spike Protein-Induced Apoptosis, Inflammatory, and Oxidative Stress Responses in THP-1-Like-Macrophages: Potential Role of Angiotensin-Converting Enzyme Inhibitor (Perindopril) , 2021, Frontiers in Immunology.
[54] Z. Rao,et al. Structural biology of SARS-CoV-2 and implications for therapeutic development , 2021, Nature Reviews Microbiology.
[55] Steven C. Johnson,et al. HIV and COVID-19: review of clinical course and outcomes , 2021, HIV research & clinical practice.
[56] J. Zoladz,et al. Lowered Serum Testosterone Concentration Is Associated With Enhanced Inflammation and Worsened Lipid Profile in Men , 2021, Frontiers in Endocrinology.
[57] Wenfang Wang,et al. A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response , 2021, Signal Transduction and Targeted Therapy.
[58] A. Sigalov. SARS-CoV-2 may affect the immune response via direct inhibition of T cell receptor: Mechanistic hypothesis and rationale , 2021, Biochimie.
[59] Jianguo Wu,et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation , 2021, Nature Communications.
[60] S. Olatunji,et al. Comorbidities and Risk Factors for Severe Outcomes in COVID-19 Patients in Saudi Arabia: A Retrospective Cohort Study , 2021, Journal of multidisciplinary healthcare.
[61] J. Olivares,et al. Microglia: The Real Foe in HIV-1-Associated Neurocognitive Disorders? , 2021, Biomedicines.
[62] R. Zhou,et al. NLRP3 inflammasome activation and cell death , 2021, Cellular & Molecular Immunology.
[63] Weitao Li,et al. SARS‐CoV‐2 nucleocapsid suppresses host pyroptosis by blocking Gasdermin D cleavage , 2021, The EMBO journal.
[64] Christopher M. Jones,et al. Substance Use among Men Who Have Sex with Men. , 2021, The New England journal of medicine.
[65] D. Leach,et al. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells , 2021, Nature Communications.
[66] M. VanElzakker,et al. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms , 2021, Frontiers in Microbiology.
[67] Shruti Gupta,et al. Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm , 2021, Indian Journal of Clinical Biochemistry.
[68] M. Hallek,et al. Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19 , 2021, EMBO molecular medicine.
[69] L. Kang,et al. A Review of Neurological Involvement in Patients with SARS-CoV-2 Infection , 2021, Medical science monitor : international medical journal of experimental and clinical research.
[70] S. Pujari,et al. Long‐coronavirus disease among people living with HIV in western India: An observational study , 2021, Immunity, inflammation and disease.
[71] D. Kell,et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin , 2021, Cardiovascular Diabetology.
[72] D. Kuritzkes,et al. COVID-19 and HIV infection co-pandemics and their impact: a review of the literature , 2021, AIDS Research and Therapy.
[73] Yang Guo,et al. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration , 2021, Frontiers in Immunology.
[74] Xiaozhong Peng,et al. The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys , 2021, Signal Transduction and Targeted Therapy.
[75] G. Lanzieri,et al. Sex-differences in COVID-19 associated excess mortality is not exceptional for the COVID-19 pandemic , 2021, Scientific Reports.
[76] M. Adelman,et al. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy , 2021, Annals of Internal Medicine.
[77] M. Hernán,et al. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy , 2021, Annals of Internal Medicine.
[78] K. Pruitt,et al. SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack , 2021, HIV/AIDS.
[79] V. Chinchilli,et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis , 2021, Scientific Reports.
[80] S. Spector,et al. SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway , 2021, iScience.
[81] D. Saylor,et al. HIV in the Brain , 2021, Neurology.
[82] M. Adesina,et al. COVID‐19: Learning from the HIV/AIDS pandemic response in Africa , 2021, The International journal of health planning and management.
[83] E. Engler-Chiurazzi,et al. SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders , 2021, Cytokine & Growth Factor Reviews.
[84] M. Montano. PRESSING QUESTIONS AND CHALLENGES IN THE HIV-1 AND SARS-COV-2 SYNDEMIC. , 2021, AIDS research and human retroviruses.
[85] Alaa Al-hindawi,et al. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone , 2021, Inflammation.
[86] M. Lasso,et al. Clinical characteristics and outcomes of people living with HIV hospitalized with COVID-19: a nationwide experience , 2021, International journal of STD & AIDS.
[87] Benjamin Bowe,et al. High-dimensional characterization of post-acute sequelae of COVID-19 , 2021, Nature.
[88] J. Hochman,et al. C-reactive protein and clinical outcomes in patients with COVID-19 , 2021, European heart journal.
[89] S. Farhadian,et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain , 2021, The Journal of experimental medicine.
[90] T. Solomon. Neurological infection with SARS-CoV-2 — the story so far , 2021, Nature Reviews Neurology.
[91] J. Girón-González,et al. Similarities and differences between HIV and SARS-CoV-2 , 2021, International journal of medical sciences.
[92] K. Bhaskaran,et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform , 2020, The Lancet HIV.
[93] D. Perl,et al. Microvascular Injury in the Brains of Patients with Covid-19 , 2020, The New England journal of medicine.
[94] J. Lazarus,et al. HIV care models during the COVID-19 era , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[95] S. Lucas. Pandemics and pathology: a reflection on influenza, HIV/AIDS and SARS (COVID-19) pandemic infections , 2020, Diagnostic Histopathology.
[96] J. Routy,et al. Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System , 2020, Frontiers in Immunology.
[97] C. Conrad,et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 , 2020, Nature Neuroscience.
[98] Hongyu Zhao,et al. Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men , 2020, Cell Stem Cell.
[99] J. Margolick,et al. COVID-19 symptoms and SARS-CoV-2 infection among people living with HIV in the US: the MACS/WIHS combined cohort study , 2020, HIV research & clinical practice.
[100] Rowena Johnston. The first 6 months of HIV-SARS-CoV-2 coinfection: outcomes for 6947 individuals , 2020, Current opinion in HIV and AIDS.
[101] M. Raji,et al. The Impact of Substance Use Disorder on COVID-19 Outcomes. , 2020, Psychiatric services.
[102] N. Arinaminpathy,et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis , 2020, EClinicalMedicine.
[103] A. Helenius,et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity , 2020, Science.
[104] J. Mehta,et al. Hypothesis: Sex-Related Differences in ACE2 Activity May Contribute to Higher Mortality in Men Versus Women With COVID-19 , 2020, Journal of cardiovascular pharmacology and therapeutics.
[105] N. Kumarasamy,et al. Impact of COVID-19 on people living with HIV: A review , 2020, Journal of Virus Eradication.
[106] A. Andrews,et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood–brain barrier , 2020, Neurobiology of Disease.
[107] Bilal Ahmad,et al. Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics , 2020, Infection, Genetics and Evolution.
[108] I. Koralnik,et al. Frequent neurologic manifestations and encephalopathy‐associated morbidity in Covid‐19 patients , 2020, Annals of clinical and translational neurology.
[109] M. Aepfelbacher,et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series , 2020, The Lancet Neurology.
[110] B. Fielding,et al. Insult to injury- potential contribution of COVID-19 to neuroinflammation and the development of HIV-associated neurocognitive disorders. , 2020, AIDS research and human retroviruses.
[111] Catherine Z. Chen,et al. Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium , 2020, Cell Stem Cell.
[112] A. Okoh,et al. Clinical outcomes of patients with COVID‐19 and HIV coinfection , 2020, Journal of medical virology.
[113] N. Volkow,et al. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States , 2020, Molecular Psychiatry.
[114] C. Iwu,et al. Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection with HIV: clinical case series analysis in North Central Nigeria , 2020, The Pan African medical journal.
[115] F. Hashmi,et al. Concerns of HIV-positive migrant workers in COVID-19 pandemic: A call for action , 2020, Journal of global health.
[116] J. Choreño-Parra,et al. Neurological Aspects of SARS-CoV-2 Infection: Mechanisms and Manifestations , 2020, Frontiers in Neurology.
[117] C. Scagnolari,et al. Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection , 2020, Medicine.
[118] J. Becker,et al. Studying the neuropsychological sequelae of SARS-CoV-2: lessons learned from 35 years of neuroHIV research , 2020, Journal of NeuroVirology.
[119] S. Farhadian,et al. Sex differences in immune responses that underlie COVID-19 disease outcomes , 2020, Nature.
[120] Mark E. Howard,et al. Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[121] Y. Hadi,et al. Characteristics and outcomes of COVID-19 in patients with HIV: a multi-center research network study. , 2020, AIDS.
[122] R. Glaubius,et al. Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models , 2020, The lancet. HIV.
[123] V. Garovic,et al. COVID-19 and Sex Differences , 2020, Mayo Clinic Proceedings.
[124] R. Bhopal,et al. Sex differential in COVID-19 mortality varies markedly by age , 2020, The Lancet.
[125] J. Gomes,et al. Neuropathogenesis of SARS-CoV-2 infection , 2020, eLife.
[126] M. Arosio,et al. SARS‐CoV‐2 infection in persons living with HIV: A single center prospective cohort , 2020, Journal of medical virology.
[127] Dhavan V. Shah,et al. Potential Influences of the COVID-19 Pandemic on Drug Use and HIV Care Among People Living with HIV and Substance Use Disorders: Experience from a Pilot mHealth Intervention , 2020, AIDS and Behavior.
[128] H. Gendelman,et al. The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections , 2020, Journal of Neuroimmune Pharmacology.
[129] P. Adadi,et al. HIV/SARS‐CoV‐2 coinfection: A global perspective , 2020, Journal of medical virology.
[130] Yangang Wang,et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.
[131] J. Schneider,et al. What HIV in the brain can teach us about SARS-CoV-2 neurologic complications? , 2020, AIDS research and human retroviruses.
[132] G. Paolisso,et al. Covid-19 Kills More Men Than Women: An Overview of Possible Reasons , 2020, Frontiers in Cardiovascular Medicine.
[133] B. Woodward,et al. Coronavirus disease 2019 (COVID‐19) outcomes in HIV/AIDS patients: a systematic review , 2020, HIV medicine.
[134] H. Khorramdelazad,et al. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics , 2020, Life Sciences.
[135] G. Pokhrel,et al. Neurological manifestations of COVID-19: a systematic review , 2020, Critical Care.
[136] A. Manini,et al. Opioid Use Disorder and COVID-19: Biological Plausibility for Worsened Outcomes , 2020, Substance use & misuse.
[137] B. Mulsant,et al. COVID-19 and persons with substance use disorders: Inequities and mitigation strategies , 2020, Substance abuse.
[138] P. Lara,et al. Age-induced NLRP3 Inflammasome Over-activation Increases Lethality of SARS-CoV-2 Pneumonia in Elderly Patients , 2020, Aging and disease.
[139] S. Friedman,et al. Challenges posed by COVID‐19 to people who inject drugs and lessons from other outbreaks , 2020, Journal of the International AIDS Society.
[140] M. Peluso,et al. Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV. , 2020, The Journal of infectious diseases.
[141] V. Valcour,et al. Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy , 2020, Frontiers in Immunology.
[142] Hong-Wei Sun,et al. Sex differences in neutrophil biology modulate response to type I interferons and immunometabolism , 2020, Proceedings of the National Academy of Sciences.
[143] L. Smirnova,et al. Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2. , 2020, ALTEX.
[144] M. Hernán,et al. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy , 2020, Annals of Internal Medicine.
[145] Pardis C Sabeti,et al. Neuropathological Features of Covid-19 , 2020, The New England journal of medicine.
[146] Madeline A. Lancaster,et al. Human CNS barrier-forming organoids with cerebrospinal fluid production , 2020, Science.
[147] S. Klein,et al. Considering how biological sex impacts immune responses and COVID-19 outcomes , 2020, Nature Reviews Immunology.
[148] A. Caliendo,et al. Intersecting Pandemics: Impact of SARS-CoV-2 (COVID-19) Protective Behaviors on People Living With HIV, Atlanta, Georgia , 2020, Journal of acquired immune deficiency syndromes.
[149] P. Adadi,et al. Living with HIV in the time of COVID‐19: A glimpse of hope , 2020, Journal of medical virology.
[150] X. Mao,et al. Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak. , 2020, ACS chemical neuroscience.
[151] C. Ruiz,et al. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease , 2020, Cytokine & Growth Factor Reviews.
[152] M. Horberg,et al. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016 , 2020, JAMA network open.
[153] I. Holloway,et al. COVID‐19 vulnerability among people who use drugs: recommendations for global public health programmes and policies , 2020, Journal of the International AIDS Society.
[154] Noga Shalev,et al. Clinical Characteristics and Outcomes in People Living With Human Immunodeficiency Virus Hospitalized for Coronavirus Disease 2019 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[155] Dan J Stein,et al. Peripheral immune dysregulation in the ART era of HIV-associated neurocognitive impairments: A systematic review , 2020, Psychoneuroendocrinology.
[156] Zhi-qiang Zhou,et al. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms , 2020, Journal of Neurology.
[157] R. King,et al. “Everything is a Mess”: How COVID-19 is Impacting Engagement with HIV Testing Services in Rural Southwestern Uganda , 2020, AIDS and Behavior.
[158] The Lancet Hiv. Lockdown fears for key populations , 2020, The Lancet HIV.
[159] P. Carmeliet,et al. COVID-19: the vasculature unleashed , 2020, Nature Reviews Immunology.
[160] A. Harky,et al. Neurological Manifestations of COVID-19: A review. , 2020, Acta neurologica Scandinavica.
[161] S. Kuchukhidze,et al. COVID-19, HIV, and Migrant Workers: The Double Burden of the Two Viruses. , 2020, AIDS patient care and STDs.
[162] A. Giacomelli,et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[163] Victor G. Puelles,et al. Multiorgan and Renal Tropism of SARS-CoV-2 , 2020, The New England journal of medicine.
[164] B. Lambert,et al. What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control? , 2020, Tropical Medicine and Health.
[165] A. Horban,et al. HIV care in times of the COVID-19 crisis — Where are we now in Central and Eastern Europe? , 2020, International Journal of Infectious Diseases.
[166] Garima Sharma,et al. Sex Differences in Mortality From COVID-19 Pandemic , 2020, JACC: Case Reports.
[167] C. Hopkins,et al. Early recovery following new onset anosmia during the COVID-19 pandemic – an observational cohort study , 2020, Journal of Otolaryngology - Head & Neck Surgery.
[168] R. Pinto,et al. COVID-19 Pandemic Disrupts HIV Continuum of Care and Prevention: Implications for Research and Practice Concerning Community-Based Organizations and Frontline Providers , 2020, AIDS and Behavior.
[169] C. Macintyre,et al. Public health, health systems and palliation planning for COVID‐19 on an exponential timeline , 2020, The Medical journal of Australia.
[170] Kristen D. Krause,et al. The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective , 2020, AIDS and Behavior.
[171] Carl H. June,et al. Cytokine release syndrome in severe COVID-19 , 2020, Science.
[172] Felipe García,et al. COVID-19 in patients with HIV: clinical case series , 2020, The Lancet HIV.
[173] Daeui Park,et al. Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor , 2020, ACS nano.
[174] C. Conrad,et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. , 2020, The EMBO journal.
[175] R. Butowt,et al. SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection , 2020, ACS chemical neuroscience.
[176] Q. Ye,et al. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.
[177] L. Mao,et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.
[178] Zhigang Wu,et al. Molecular Architecture of the SARS-CoV-2 Virus , 2020, Cell.
[179] N. Enomoto,et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 , 2020, International Journal of Infectious Diseases.
[180] A. Verkhratsky,et al. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID‐19 , 2020, Acta physiologica.
[181] Russell B. Fletcher,et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia , 2020, Science Advances.
[182] A. Giacomelli,et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[183] Xiaowei Li,et al. Molecular immune pathogenesis and diagnosis of COVID-19 , 2020, Journal of Pharmaceutical Analysis.
[184] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[185] A. M. Leontovich,et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.
[186] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[187] Bo Diao,et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.
[188] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[189] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[190] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.
[191] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[192] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[193] Dong-Yan Jin,et al. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses , 2020, Emerging microbes & infections.
[194] M. Villacres,et al. Loss of Pre-Existing Immunological Memory among HIV Infected Women Despite Immune Reconstitution with Antiretroviral Therapy. , 2019, The Journal of infectious diseases.
[195] C. Van Lint,et al. Microglial Cells: The Main HIV-1 Reservoir in the Brain , 2019, Front. Cell. Infect. Microbiol..
[196] E. Masliah,et al. NLRP3-dependent pyroptosis is required for HIV-1 gp120-induced neuropathology , 2019, Cellular & Molecular Immunology.
[197] Yuan He,et al. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation , 2019, International journal of molecular sciences.
[198] P. Palma,et al. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART , 2019, Viruses.
[199] I. Grant,et al. Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection , 2018, Molecular Neurobiology.
[200] Shengdi Chen,et al. Blood-Brain Barrier Disruption Induced Cognitive Impairment Is Associated With Increase of Inflammatory Cytokine , 2018, Front. Aging Neurosci..
[201] D. Swendeman,et al. Mental Health and Substance Use Disorder Comorbidity among Methamphetamine-Using Men Who have Sex with Men , 2018, Journal of psychoactive drugs.
[202] M. Young,et al. Variability in C-reactive protein is associated with cognitive impairment in women living with and without HIV: a longitudinal study , 2018, Journal of NeuroVirology.
[203] R. Hogg,et al. Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. , 2017, The lancet. HIV.
[204] Mark Obermann,et al. HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment , 2017, Journal of Neurology.
[205] B. Maughan-Brown,et al. Improved life expectancy of people living with HIV: who is left behind? , 2017, The lancet. HIV.
[206] M. Gougeon. Alarmins and central nervous system inflammation in HIV‐associated neurological disorders , 2017, Journal of internal medicine.
[207] S. Buch,et al. HIV-1 Tat Primes and Activates Microglial NLRP3 Inflammasome-Mediated Neuroinflammation , 2017, The Journal of Neuroscience.
[208] W. Stenzel,et al. Acute and chronic viral infections. , 2017, Handbook of clinical neurology.
[209] S. Lewin,et al. HIV persistence and T-cell activation in blood, rectal and lymph node tissue in HIV-infected individuals receiving suppressive ART. , 2017, The Journal of infectious diseases.
[210] N. Nakasujja,et al. Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda , 2016, Journal of NeuroVirology.
[211] C. Power,et al. HIV-1 Viral Protein R Activates NLRP3 Inflammasome in Microglia: implications for HIV-1 Associated Neuroinflammation , 2017, Journal of Neuroimmune Pharmacology.
[212] J. Margolick,et al. Effect of HIV-infection and cumulative viral load on age-related decline in grip strength , 2016, AIDS.
[213] A. Winston,et al. Defining cognitive impairment in people-living-with-HIV: the POPPY study , 2016, BMC Infectious Diseases.
[214] Jerome H. Kim,et al. Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals , 2016, AIDS.
[215] David J. Volsky,et al. HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment , 2016, Nature Reviews Neurology.
[216] M. Saleem,et al. HIV Promotes NLRP3 Inflammasome Complex Activation in Murine HIV-Associated Nephropathy. , 2016, The American journal of pathology.
[217] Jonathan Kipnis,et al. Revisiting the Mechanisms of CNS Immune Privilege. , 2015, Trends in immunology.
[218] A. Phillips,et al. Factors Associated With Plasma IL-6 Levels During HIV Infection. , 2015, The Journal of infectious diseases.
[219] Paul E. Gilbert,et al. Elevated rates of mild cognitive impairment in HIV disease , 2015, Journal of NeuroVirology.
[220] D. McGavern,et al. Viral diseases of the central nervous system. , 2015, Current opinion in virology.
[221] Meng Xu,et al. The Relationship of CSF and Plasma Cytokine Levels in HIV Infected Patients with Neurocognitive Impairment , 2015, BioMed research international.
[222] I. Grant,et al. Abdominal Obesity Contributes to Neurocognitive Impairment in HIV-Infected Patients With Increased Inflammation and Immune Activation , 2015, Journal of acquired immune deficiency syndromes.
[223] G. Guaraldi,et al. Hypogonadism in the HIV-infected man. , 2014, Endocrinology and metabolism clinics of North America.
[224] G. Guaraldi,et al. Multimorbidity and functional status assessment. , 2014, Current opinion in HIV and AIDS.
[225] M. Lederman,et al. HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality , 2014, PLoS pathogens.
[226] Maureen H Richards,et al. β-Catenin/TCF-4 signaling regulates susceptibility of macrophages and resistance of monocytes to HIV-1 productive infection. , 2014, Current HIV research.
[227] P. Böelle,et al. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[228] A. Lorenc,et al. The prevalence of comorbidities among people living with HIV in Brent: a diverse London Borough , 2014, London journal of primary care.
[229] James J. Goedert,et al. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.
[230] K. Tashima,et al. Relationship of plasma cytokines and clinical biomarkers to memory performance in HIV , 2013, Journal of Neuroimmunology.
[231] B. Ances,et al. HIV-associated neurocognitive disorder. , 2013, The Lancet. Infectious diseases.
[232] D. Douek,et al. Systemic effects of inflammation on health during chronic HIV infection. , 2013, Immunity.
[233] Jennifer A. Pellowski,et al. A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. , 2013, The American psychologist.
[234] N. Ford,et al. Life Expectancy of Persons Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort Analysis From Uganda , 2011, Annals of Internal Medicine.
[235] J. Nachega,et al. HIV treatment adherence, drug resistance, virologic failure: Evolving concepts , 2022 .
[236] R. Ownby,et al. Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains , 2009, Journal of NeuroVirology.
[237] Andrew V. Albright,et al. Pathogenesis of human immunodeficiency virus-induced neurological disease , 2003, Journal of NeuroVirology.
[238] F. Sutterwala,et al. The NLRP3 inflammasome: a sensor of immune danger signals. , 2009, Seminars in immunology.
[239] S. Mahajan,et al. SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-κB pathway in human monocyte macrophages in vitro , 2009, Virus Research.
[240] Ross J. Harris,et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.
[241] David K. Meyerholz,et al. Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the Absence of Encephalitis in Mice Transgenic for Human ACE2 , 2008, Journal of Virology.
[242] J. Becker,et al. Updated research nosology for HIV-associated neurocognitive disorders , 2007, Neurology.
[243] E. Lazartigues,et al. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.
[244] T. Kielian. Toll‐like receptors in central nervous system glial inflammation and homeostasis , 2006, Journal of neuroscience research.
[245] N. Zhong,et al. Detection of Severe Acute Respiratory Syndrome Coronavirus in the Brain: Potential Role of the Chemokine Mig in Pathogenesis , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[246] Francisco González-Scarano,et al. The neuropathogenesis of AIDS , 2005, Nature Reviews Immunology.
[247] Jeffrey N. Martin,et al. Central Memory CD4+ T Cell Responses in Chronic HIV Infection Are Not Restored by Antiretroviral Therapy1 , 2004, The Journal of Immunology.
[248] E. Lavi,et al. Coronavirus Neurovirulence Correlates with the Ability of the Virus To Induce Proinflammatory Cytokine Signals from Astrocytes and Microglia , 2004, Journal of Virology.
[249] H. Gendelman,et al. Mononuclear phagocyte immunity and the neuropathogenesis of HIV‐1 infection , 2003, Journal of leukocyte biology.
[250] Y. Shoenfeld,et al. HIV and autoimmunity. , 2002, Autoimmunity reviews.
[251] F. Scaravilli,et al. Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. , 1999, Journal of neuropathology and experimental neurology.
[252] M. Weinand,et al. A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. , 1997, Journal of immunology.
[253] H. Gendelman,et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. , 1996, Journal of immunology.
[254] J. Clements,et al. Molecular biology and pathogenesis of animal lentivirus infections , 1996, Clinical microbiology reviews.
[255] Robin A. Weiss,et al. How does HIV cause AIDS , 1993 .
[256] W. Wachsman,et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection , 1992, Neurology.
[257] P. Carrieri,et al. Interleukin-6 and granulocyte macrophage-CSF in the cerebrospinal fluid from HIV infected subjects with involvement of the central nervous system. , 1992, Arquivos de neuro-psiquiatria.
[258] L. Resnick,et al. Early penetration of the blood‐brain‐barrier by HIV , 1988, Neurology.
[259] C. Wiley,et al. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[260] A. Haase. Pathogenesis of lentivirus infections , 1986, Nature.
[261] R. Schooley,et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. , 1985, The New England journal of medicine.
[262] Michael S. B. Edwards,et al. A Trojan Horse mechanism for the spread of visna virus in monocytes. , 1985, Virology.
[263] D. Longo,et al. Acquired Immunodeficiency Syndrome: Epidemiologic, Clinical, Immunologic, and Therapeutic Considerations , 1984 .